Related Experiment Video
Updated: May 11, 2026
09:14
Pre-Chiasmatic, Single Injection of Autologous Blood to Induce Experimental Subarachnoid Hemorrhage in a Rat Model
Published on: June 18, 2021
Cholesterol-reducing agents for aneurysmal subarachnoid haemorrhage.
Zhou Liu1, Lingying Liu, Zhijian Zhang
1Department of Neurology, Affiliated Hospital of Guangdong Medical College, Zhanjiang, China. zhaobine@163.net.
The Cochrane Database of Systematic Reviews
|May 2, 2013
Summary
Cholesterol-reducing agents like simvastatin did not significantly reduce delayed ischaemic deficits in aneurysmal subarachnoid haemorrhage patients. More research is needed to confirm effectiveness and safety.
Area of Science:
- Neurology
- Cardiovascular Research
Background:
- Aneurysmal subarachnoid haemorrhage (SAH) frequently leads to cerebral vasospasm and delayed ischaemic deficits (DIDs), impacting patient outcomes.
- Cholesterol-reducing agents are being investigated for their potential to mitigate these adverse effects.
Purpose of the Study:
- To evaluate the efficacy of cholesterol-reducing agents in improving outcomes for patients following aneurysmal SAH.
Main Methods:
- Conducted a systematic search of multiple databases (Cochrane, MEDLINE, EMBASE, SinoMed, CNKI, VIP) and clinical trial registers.
- Included one randomized controlled trial (RCT) comparing simvastatin with placebo in patients with aneurysmal SAH.
Main Results:
- The single RCT involved 39 patients; simvastatin showed a non-significant trend towards reducing DIDs (26% vs. 60%).
- No significant impact on DIDs was observed, and the primary outcome of death or dependency at six months was not reported.
- Adverse events included elevated liver enzymes and creatine phosphokinase in a small number of patients.
Conclusions:
- Insufficient evidence exists to conclude on the effectiveness and safety of cholesterol reduction in aneurysmal SAH due to the limited data from one small trial.
- Further randomized controlled trials are necessary to establish the role of these agents in managing SAH complications.
Related Concept Videos
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...